Axsome Therapeutics Inc (AXSM)
75.19
+1.01
(+1.36%)
USD |
NASDAQ |
May 24, 16:00
75.28
+0.10
(+0.13%)
After-Hours: 20:00
Axsome Therapeutics Enterprise Value: 3.418B for May 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 24, 2024 | 3.418B |
| May 23, 2024 | 3.370B |
| May 22, 2024 | 3.494B |
| May 21, 2024 | 3.558B |
| May 20, 2024 | 3.532B |
| May 17, 2024 | 3.483B |
| May 16, 2024 | 3.521B |
| May 15, 2024 | 3.454B |
| May 14, 2024 | 3.521B |
| May 13, 2024 | 3.440B |
| May 10, 2024 | 3.291B |
| May 09, 2024 | 3.347B |
| May 08, 2024 | 3.442B |
| May 07, 2024 | 3.502B |
| May 06, 2024 | 3.454B |
| May 03, 2024 | 3.400B |
| May 02, 2024 | 3.371B |
| May 01, 2024 | 3.404B |
| April 30, 2024 | 3.351B |
| April 29, 2024 | 3.347B |
| April 26, 2024 | 3.253B |
| April 25, 2024 | 3.244B |
| April 24, 2024 | 3.227B |
| April 23, 2024 | 3.318B |
| April 22, 2024 | 3.224B |
| Date | Value |
|---|---|
| April 19, 2024 | 3.072B |
| April 18, 2024 | 2.969B |
| April 17, 2024 | 3.158B |
| April 16, 2024 | 3.115B |
| April 15, 2024 | 3.087B |
| April 12, 2024 | 3.129B |
| April 11, 2024 | 3.252B |
| April 10, 2024 | 3.216B |
| April 09, 2024 | 3.295B |
| April 08, 2024 | 3.270B |
| April 05, 2024 | 3.277B |
| April 04, 2024 | 3.273B |
| April 03, 2024 | 3.336B |
| April 02, 2024 | 3.386B |
| April 01, 2024 | 3.502B |
| March 31, 2024 | 3.635B |
| March 28, 2024 | 3.572B |
| March 27, 2024 | 3.543B |
| March 26, 2024 | 3.426B |
| March 25, 2024 | 3.456B |
| March 22, 2024 | 3.613B |
| March 21, 2024 | 3.623B |
| March 20, 2024 | 3.527B |
| March 19, 2024 | 3.434B |
| March 18, 2024 | 3.228B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
552.56M
Minimum
Oct 01 2019
4.415B
Maximum
Feb 12 2024
2.275B
Average
2.542B
Median
Mar 13 2023
Enterprise Value Benchmarks
| Krystal Biotech Inc | 4.112B |
| Catalyst Pharmaceuticals Inc | 1.564B |
| Vertex Pharmaceuticals Inc | 107.75B |
| Vistagen Therapeutics Inc | -16.30M |
| ADMA Biologics Inc | 2.302B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -68.36M |
| Revenue (Quarterly) | 75.00M |
| Total Expenses (Quarterly) | 143.69M |
| EPS Diluted (Quarterly) | -1.44 |
| Gross Profit Margin (Quarterly) | 91.60% |
| Profit Margin (Quarterly) | -91.14% |
| Earnings Yield | -8.49% |
| Normalized Earnings Yield | -7.138 |